Zurich, December 1, 2022 /PRNewswire/ — BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced Finnish Uformatics and Hungarian Oncompass Medicine, a BCP-led partnership, has won a second phase contract to develop a standardized oncology workflow for a buyer consortium of seven major hospitals* in Central Europe, represented by the Medical University of Graz. Following the announcement of May 18, 2022 Three companies in partnership to deliver Phase 1 of this Instand-NGS4P project**.
Instand-NGS4P is a Horizon 2020-funded project that shares the vision of a BC platform to improve diagnostics for cancer patients. It develops and delivers integrated and standardized workflows for next-generation sequencing (NGS) to integrate information from cancer genetic testing, pharmacogenetic testing, and electromedicine to inform medical decision-making. This is achieved by supporting The program runs in three phases until: May 2025 The total pre-commercial procurement budget is about 8 million euros (around US$8.2 million).
BC Platforms, Euformatics, and Oncompass Medicine have worked on designing the solution. After a thorough review of Phase 1 reports submitted by various providers and a Phase 2 application for prototyping, the BC platform-led partnership has been awarded a Phase 2 contract. The combination of existing IP and expertise in areas such as genomic data management, variant interpretation, NGS data quality management and precision oncology was the foundation of the winning partnership.
Kurt ZatrukarProfessor of Pathology at the Medical University of Graz, “Phase 1 of this important project, delivering a revolutionary NGS workflow, is driven by patient and clinical needs and has come a long way since our last announcement in May. BC Platforms, Euformatics, Oncompass Medicine’s consortium was selected from a highly competitive pool of applications whose applications were evaluated in a multi-stage peer review process, and we look forward to continuing this exciting collaboration in Phase 2. I have.”
Tero SilvolaCEO of BC Platform, “Following a close partnership with the talented teams at Euformatics and Oncompass Medicine, we are pleased to announce the excellent quality of this important Horizon 2020 funded project and the conclusion of the Phase 2 contract. It is about helping define clinical practice in oncology and precision medicine in the years to come. We are proud that our genomic data management platform is helping improve healthcare, the e-medical portion of the program.”
Tommi KasalainenCEO of Euformatics, “We are delighted with another win in our partnership with BC Platforms. North America, EuropeWhen AsiaOnCompass Medicine is a great addition to this partnership and offers great value. We continue this winning trio with Phase 2 of the Instand-NGS4P program, which builds on the Euformatics Genomics Hub product, in close collaboration with leading European medical institutions. “
doctor doctor Istvan PetakFounder and CEO of Oncompass Medicine“I said in May that I am looking forward to pushing the boundaries.I am delighted with how far we have been able to go, working closely with our partners. -The ultimate solution for oncologists to find the right targeted therapy for every cancer patient, based on the tumor’s entire complex molecular profile.This partnership will make it easier for hospitals to deploy better NGS services, Patients have been getting better care ever since the project ended.It’s done.”
The second phase of the project has started and the result is January 2024The Hospital Purchasing Consortium will then evaluate the performance of all Phase 2 contractors and select them to proceed to Phase 3, ultimately resulting in two standardized NGSs in 2025 as a result of the Instand-NGS4P program. Deploy and integrate workflows.
* The consortium is formed by the hospitals of the medical school. Graz of Austriauniversities in Florence University of Milano-Bicocca Italy, Erasmus University medical center NetherlandsChristian Albrecht University in Kiel and St. Anna Childhood Cancer Institute GermanyLeon Berard Center France.
** This project is co-funded by European Union Grant Agreement No. 874719.
About the BC Platform
BC Platforms is a global leader in building data networks for the life sciences industry, providing a versatile technology platform for personalized medicine and accelerating the transition of innovation to clinical practice. Transform complex biological information collected in the medical field into actionable insights. Our innovative technology creates an infinite patient-centric loop between the life sciences and healthcare sectors. The data we generate, harmonize and manage from various biobanks and medical institutions is made accessible to pharmaceutical and biotech companies to strengthen their core strengths in research and development. In parallel, it will enable patient stratification towards targeted therapies, promising more personalized healthcare.
Our high-performance genomic data discovery and analysis platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed BCRQUEST.com, a global data partner network that gives you access to high-quality real-world data. This rapidly growing network has a footprint at many sites, including a network of leading hospitals covering 20 countries on 5 continents, providing standard of care data for over 23 million patients. . Our platform seamlessly facilitates access to highly enriched data for drug research and development.
Founded in 1997 as a spin-off of the MIT Whitehead Project, we have a strong scientific legacy of working closely with a network of leading researchers, developers and industry partners for over 25 years. . We are headquartered in and operate our business globally. Zurich, SwitzerlandR&D in Espoo, FinlandWhen Singaporenot only, London and Boston.For more information visit our website website and follow us LinkedIn.
Source BC Platform
